A glimmer of hope has emerged for mesothelioma patients, a group facing an unfortunate reality with a high percentage of treatment-resistant cases. However, a recent development at the European Society for Medical Oncology Congress in Berlin has brought a ray of light to this bleak prognosis. Biotech company Vivace Therapeutics presented their groundbreaking investigational drug, VT3989, which achieved an impressive 32% objective response rate in a phase 1/2 trial. The results, published in Nature Medicine, showed that seven out of 22 patients experienced a remarkable 30% reduction in tumor size, while the tumors of another 12 patients stabilized.
But here's where it gets even more promising: the median survival time without cancer progression for the 22 mesothelioma patients in the study was a remarkable 40 weeks, more than double the standard-of-care benchmark of 15 weeks with salvage chemotherapy. This incredible outcome has led Vivace to plan a phase 3 registrational study, scheduled for the first half of 2026.
The study enrolled a total of 172 participants, including mesothelioma patients and those with other solid tumors. Importantly, none of the participants experienced dose-limiting toxicities, and only a small percentage (3.5%) discontinued treatment due to adverse events. Most side effects were classified as mild to moderate, offering a promising safety profile.
Dr. Timothy Yap, a medical oncologist and lead investigator of the trial, believes these initial findings showcase the therapeutic potential of VT3989 for mesothelioma treatment. With few options available beyond first-line therapies for this rare, asbestos-related cancer, the combination of strong efficacy and encouraging safety data makes a compelling case for further exploration.
And this is the part most people miss: VE3989, the drug behind these remarkable results, targets the Hippo pathway, a key regulator of cell growth, migration, and death. Researchers have discovered that many cancer cells, including mesothelioma, exhibit an overactive Hippo pathway. The investigational compound works by inhibiting a group of transcription factors called TEAD, which play a crucial role in regulating this pathway. If approved by the FDA, VE3989 would be the first drug to target this pathway, offering a potential breakthrough in mesothelioma treatment.
For those affected by mesothelioma, this research provides a much-needed reason to be optimistic. If you or a loved one has been diagnosed with mesothelioma, reach out to the Patient Advocates at Mesothelioma.net at 1-800-692-8608 for more information on available resources and support.
Remember, knowledge is power, and staying informed about the latest advancements in mesothelioma research and treatment is crucial. Terri Heimann Oppenheimer, the head writer of the Mesothelioma.net news blog, is dedicated to sharing stories, research updates, and medical breakthroughs to empower and educate those impacted by this devastating disease.
